Published in Pharm Res on March 01, 1993
Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene. AAPS PharmSciTech (2006) 0.92
Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA) based nanoparticles for controlled drug delivery: Effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles. Colloid Polym Sci (2013) 0.84
Novel Pentablock Copolymers as Thermosensitive Self-Assembling Micelles for Ocular Drug Delivery. Adv Pharm Bull (2017) 0.75
Nanomedicine approaches for corneal diseases. J Funct Biomater (2015) 0.75
Toxicogenomics of nanoparticulate delivery of etoposide: potential impact on nanotechnology in retinoblastoma therapy. Cancer Nanotechnol (2010) 0.75
First protein kinase structure. Science (1991) 9.25
Antigen processing: a new pathway discovered. Science (1992) 5.85
Discovery of a cool planet of 5.5 Earth masses through gravitational microlensing. Nature (2006) 3.53
Lack of association between early exposure to cow's milk protein and beta-cell autoimmunity. Diabetes Autoimmunity Study in the Young (DAISY) JAMA (1996) 3.52
Monoclonal antibodies to human cytomegalovirus: three surface membrane proteins with unique immunological and electrophoretic properties specify cross-reactive determinants. Infect Immun (1982) 3.40
Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY). Diabetologia (1996) 3.23
Yeast biology enters a surprising new phase. Science (1992) 2.70
The prevalence of primary angle closure glaucoma and open angle glaucoma in Mamre, western Cape, South Africa. Arch Ophthalmol (1993) 2.18
'Men leave me as I cannot have children': women's experiences with involuntary childlessness. Hum Reprod (2002) 1.88
Complement-fixing antibody in human sera reactive with viral and soluble antigens of cytomegalovirus. J Clin Microbiol (1975) 1.81
Polymorphism of human cytomegalovirus glycoproteins characterized by monoclonal antibodies. Virology (1984) 1.76
Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost (2004) 1.72
Pilot study of the effectiveness of the family-to-family education program. Psychiatr Serv (2001) 1.71
Electrophoretic analysis of polypeptides immune precipitated from cytomegalovirus-infected cell extracts by human sera. Infect Immun (1982) 1.71
Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics. J Allergy Clin Immunol (1979) 1.66
Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci U S A (1993) 1.58
Sleep benefit in Parkinson's disease. Mov Disord (1997) 1.56
Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. J Thromb Haemost (2007) 1.56
Generation of species cross-reactive aptamers using "toggle" SELEX. Mol Ther (2001) 1.49
Alpha-macroglobulin secreted by alveolar macrophages serves as a binding protein for a macrophage-derived homologue of platelet-derived growth factor. Am J Respir Cell Mol Biol (1989) 1.48
Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest (1998) 1.46
The cell's nucleus shapes up. Science (1993) 1.45
Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family. Hum Mol Genet (1997) 1.44
Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol (1997) 1.43
The remineralizing effect of an essential oil fluoride mouthrinse in an intraoral caries test. J Am Dent Assoc (2004) 1.42
Analysis of antibody assay methods and classes of viral antibodies in serodiagnosis of cytomegalovirus infection. J Clin Microbiol (1978) 1.41
EEG detection of nontonic-clonic status epilepticus in patients with altered consciousness. Epilepsy Res (1994) 1.40
HIV test counselling at a tertiary hospital. S Afr Med J (1995) 1.39
Hormone replacement therapy--finally, good data. S Afr Med J (2004) 1.39
Platelets contain releasable coagulation factor IX antigen. Blood Coagul Fibrinolysis (1993) 1.39
Cardiopulmonary support in the intensive care unit. Am J Crit Care (1992) 1.38
[Bactericide activity of sulbactam before bacteria belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex]. Enferm Infecc Microbiol Clin (1996) 1.38
Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function. Mov Disord (1998) 1.31
Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther (2007) 1.29
Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J Control Release (1998) 1.28
Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif. J Immunol (1993) 1.24
Variants of the VDR gene and risk of colon cancer (United States). Cancer Causes Control (2001) 1.24
Effect of the microencapsulation of nanoparticles on the reduction of burst release. Int J Pharm (2007) 1.24
Bovine mastitis and intramammary drug delivery: review and perspectives. Adv Drug Deliv Rev (2001) 1.23
Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur J Immunol (1997) 1.22
Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther (2001) 1.21
Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification. Int J Pharm (1999) 1.18
Physicomechanical properties of biodegradable poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) films in the dry and wet states. J Pharm Sci (2000) 1.18
Misoprostol for second trimester pregnancy termination in women with prior caesarean: a systematic review. BJOG (2009) 1.13
The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. Vascul Pharmacol (2006) 1.13
High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol (2001) 1.12
Effect of acriflavine and sodium dodecyl sulphate on infectiveness of Rhizobium trifolii. Acta Microbiol Pol A (1973) 1.11
Modifiable risk factors for Type 2 diabetes mellitus in a peri-urban community in South Africa. Diabet Med (1999) 1.11
Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol (1999) 1.10
Sequence variants in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. Diabetes (1996) 1.09
Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells. Biochem Biophys Res Commun (1992) 1.09
The 45XO/46XY mosaic intersex syndrome. J Med Genet (1966) 1.07
Infertility in South Africa: women's reproductive health knowledge and treatment-seeking behaviour for involuntary childlessness. Hum Reprod (2002) 1.06
Outcomes of the peer-taught 12-week family-to-family education program for severe mental illness. Acta Psychiatr Scand (2004) 1.05
Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol (2000) 1.05
Gastric duplication cyst communicating with aberrant pancreatic duct: a rare cause of recurrent acute pancreatitis. Surgery (1987) 1.05
Beta-cell autoantibodies in infants and toddlers without IDDM relatives: diabetes autoimmunity study in the young (DAISY). J Autoimmun (1996) 1.05
Community participation in the Mamre Community Health Project. S Afr Med J (1988) 1.05
Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur J Pharm Biopharm (1998) 1.03
No association of vitamin D intake or 25-hydroxyvitamin D levels in childhood with risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia (2011) 1.03
Stability study of nanoparticles of poly(epsilon-caprolactone), poly(D,L-lactide) and poly(D,L-lactide-co-glycolide). Biomaterials (1996) 1.02
Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol (2000) 1.02
Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique. Int J Pharm (2000) 1.00
Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs. J Thromb Haemost (2006) 0.99
Challenges in implementing a cervical screening program in South Africa. Cancer Detect Prev (2006) 0.99
A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis (1998) 0.99
Preparation and characterization of ethylcellulose microspheres containing 5-fluorouracil. J Microencapsul (1995) 0.98
Disposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles. J Pharm Sci (1986) 0.97
Recessive inheritance of obesity in familial non-insulin-dependent diabetes mellitus, and lack of linkage to nine candidate genes. Am J Hum Genet (1997) 0.97
Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy. J Control Release (1999) 0.97
Transmission of a procoagulant signal from tissue factor-bearing cell to platelets. Blood Coagul Fibrinolysis (1996) 0.96
Cytomegalovirus-infected cell polypeptides immune-precipitated by sera from children with congenital and perinatal infections. Infect Immun (1983) 0.96
Epidemiology of achalasia in central Israel. Rarity of esophageal cancer. Dig Dis Sci (1993) 0.95
Cardiovascular responses to carotid and vertebral artery infusions of propranolol. Cardiovasc Res (1971) 0.95
Susceptibility of beta-hemolytic streptococci to nine antimicrobial agents among four medical centers in Salt Lake City, Utah, USA. Diagn Microbiol Infect Dis (1997) 0.95
Analyzing fibrin clot structure using a microplate reader. Blood Coagul Fibrinolysis (2002) 0.94
Comparison of the effects of IL-1 alpha and TNF-alpha on phagocyte accumulation and murine antibacterial immunity. Cell Immunol (1989) 0.94
Cost-effectiveness analysis of recruitment strategies in a community-based intervention study of HIV-infected persons. AIDS Care (2003) 0.94
Liposarcoma complicating pregnancy. Gynecol Oncol (2001) 0.93
[A new etiology of episcleritis: nephropathies with IgA and/or isolated C3 deposits]. J Fr Ophtalmol (1983) 0.93
Ventilatory response of spinal cord-lesioned subjects to electrically induced exercise. J Appl Physiol (1985) (1990) 0.93
The consequences of aortic calcium overload following vitamin D3 plus nicotine treatment in young rats. J Hypertens (1991) 0.93
Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats. Pharm Res (1992) 0.93
Influence of the preparation method on the physicochemical properties of tolbutamide/cyclodextrin binary systems. Drug Dev Ind Pharm (2001) 0.92
Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles. Int J Pharm (2005) 0.92
The influence of morphological variation on Candida albicans adhesion to denture acrylic in vitro. Arch Oral Biol (1992) 0.92
Preparation and characterization of heparin-loaded polymeric microparticles. Drug Dev Ind Pharm (2002) 0.91
Severe inflammatory upper airway stenosis in ulcerative colitis. Eur Respir J (1994) 0.91
Alpha 2-macroglobulin 'fast' forms inhibit superoxide production by activated macrophages. Biochim Biophys Acta (1983) 0.91
Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. J Thromb Haemost (2003) 0.90